KevinCompounds said:

The liver data is among the strongest non-weight findings in the class.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Dr.EndoIndy said:

The mechanism that matters here is not stomach emptying, it is central.

Genuinely useful, thank you. I had the facts and not the framework.

KevinCompounds said:

The liver data is among the strongest non-weight findings in the class.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

The figures, for anyone assembling their own picture. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

Happy to go further on any of that.

Moderator note: the sourcing question belongs in the vendor section and has been split out. Report rather than reply if it drifts again.